Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will see what is available in my area. Luckily my state will order it and has a database to see where different ones are sold.
Yup, exactly
Thank you, we will see how it all unfolds. I told myself March before I make a decision of pulling out but I may extend that to June.
I am on their website now. What are everyone's top 3? I might as well add to my cabinet at home :)
Thanks, I am holding on this long term. I work in a city where there is a lot of competition of different sin beverages and have some insight to the market forces at play. It's a fun play and Soldier introduced me to this stock, so why not? I just need to go find some to drink now!
Only if! I hope to ask a few questions on their next conference call about their business if I get a chance. Unfortunately, I am at work so I am unable to look at the level 2 through TDAmeritrade. I imagine this will be a slow climb to 2 unless their Q1+ FY 16' really are mind blowing- it's a solid company though so I am not worried at all. Their P/E should be higher though!
Agreed, I am sitting on 4k shares right now. II am considering picking up some more soon too. The range has been tight and the companies growth has been organic so I am surprised this gem has not been picked up by institutions. The one negative thing is their lack of diversity of clients though I imagine that is something they are working on.
Picking up a few hundred shares here and there each week now with this one.
Keeps moving slowly higher and higher. I'm happy for it's price action this week though it's still swinging 7% in both ways!
Either way it impacts their business model significantly. I hope they cancel the contract with MIDAM and use that money to buy back/retire shares. That would be a reasonable next step IMO.
I wonder what the time frame will be for FY 16' audited financials. Any guess at what time frame that might be? I recall someone saying Q1 but I could be totally wrong.
I will say that if they have a business plan that is flexible and are able to expand into other markets outside of the current specialty market they are in, there is a lot of opportunity for this company to grow. A concern for me is that they have not factored in the damage could be done if the ACA is revoked. All plans that have been presented as alternatives have been evaluated by the RAND Corp and KFF which only show negative impact w/ patient care & cost to the economy. This is a much larger issue than just RXMD but it will impact their business model as it is now.
Outside of that I am still critical of the company but their choice in auditors are spot on. Best news to me in the last 5 months.
I am looking into this company and so far they appear like a solid choice. I am super critical of RXMD but this is the first time I have felt that a PR had a lot of meat.
Couldn't of said it better!
All they need to do is buy back the shares they gave to MIDAM. 50k a day :)
Thank you, I am slowly accumulating more shares of this and hopfully I will find myself some to drink!
Well it looks like I am a new owner of ROX so I decided to come drop in and say hello.
True, I imagine it's going to continue to have positive earning reports. They are up 10% YOY so that speaks volumes since last year aside the Q3 report was stellar. I imagine they are doing a new business line or their commercial products are being adopted by the public more.
Likewise, I feel there is going to be another pop. It's in a tight range right now but I have not been watching level 2 this week. I am curious what the plays have been on it.
Here is is the IR report on earnings at this end of this year:
VICTORIA, BC / ACCESSWIRE / January 19, 2017 / FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE MKT: FSI, FRA: FXT) is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients, and water treatment, as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today, the Company announces a year over year increase in revenue for fourth quarter (Q4) and full year 2016.
Flexible Solutions' top line quarterly revenue increased from $3.731 million (Q4, 2015) to $4.090 million (Q4, 2016), up approximately 10% year over year. Full year 2016 revenue was $16.253 million, up 2%, compared to sales of $15.899 million during the same period in 2015.
Complete financial results will be available after market close on Friday March 31, 2017, concurrent with our SEC quarterly filings. A conference call will be scheduled for 8:00am Pacific Time, 11:00 am Eastern Standard Time, on Monday, April 3, 2017. To participate in the conference call, see the FSI March 31, 2017 financials news release for the dial in numbers.
About Flexible Solutions International
Flexible Solutions International, Inc. (www.flexiblesolutions.com), based in Victoria, British Columbia, is an environmental technology company. The Company's NanoChem Solutions Inc. subsidiary specializes in biodegradable, water-soluble products utilizing thermal polyaspartate (TPA) biopolymers. TPA beta-proteins are manufactured from the common biological amino acid, L-aspartic, and have wide usage, including scale inhibitors, detergent ingredients, water treatment, and crop enhancement. The other divisions manufacture energy and water conservation products for drinking water, agriculture, industrial markets, and swimming pools throughout the world. FSI is the developer and manufacturer of WaterSavrTM, the world's first commercially viable water evaporation retardant. WaterSavrTM reduces evaporation by up to 30% on reservoirs, lakes, aqueducts, irrigation canals, ponds, and slow moving rivers. HeatsavrTM, a "liquid blanket" evaporation retardant for the commercial swimming pool and spa markets, reduces energy costs by 15% to 40% and can result in reduced indoor pool humidity. The Company's EcosavrTM product targets the residential swimming pool market providing the same savings as HeatsavrTM.
An excellent write up on FSI and why it's a solid buy over at Seeking Alpha:
http://seekingalpha.com/article/4037775-asymmetric-allocation-3-reasons-flexible-solutions-bioamber-great-long-short-story
I am impressed that it moved EXACTLY like it did Friday. I mean could it be frozen in time?! :P
I am an investor too in this company however their are some within the organization that make all their deals suspect. Honestly the collusion between MIDAM and RXMD is suspect. I think that it might be acting as a tax shelter and shell company. Until they provide substantial evidence that supports all the claims they have made I will be not investing more money.
Either way I hope I am wrong and this skyrockets.
I couldn't agree more. I am going to give this company 3 months to show it's worth.
It besmirches me some knowing that they are not listening to the message of the stock holder. I am going to try to touch base with the IR tomorrow to further discuss my concerns if I have time. If this company is so amazing and under valued it would take only 10 million to buyout all of the stocks floating around- more specifically 5 million. A hostile takeover could be easy to do if these large groups had any intention so it makes me ponder how much is fluff and how much is reality based. I originally was planning on taking a large state in this company but it has not shown me that it has the backbone for such an investment.
I know you have put in a significant amount of your money (based on your posts) so I hope that you are rewarded but how do we put fire under their ass to get them to move. These PR about sales mean nothing if they cannot move the SP an inch.
Recently a large portion of patients with a specific disease was able to lobby congress to expedite the medication through. The first article was a success story of patients advocating for the experimental drugs being pushed through quicker, Sarepta is the drug manufacture.
http://www.syracuse.com/news/index.ssf/2016/04/cny_mom_twin_sons_to_testify_before_fda_panel_for_approval_of_experimental_drug.html
https://ww2.kqed.org/stateofhealth/2017/01/02/will-californias-new-right-to-try-law-empower-or-exploit-patients/
However, the issue is it will not impact the PPS and will continue to go sideways until there is meaningful things such as audited financials, insider buying, and uplisting taking place. Until then, to me, it's all hot air. I will sit on my shares until this tanks or thrives.
Totally possible and a very cool story if true.
Correct, but they rely on ones that are accessible by any company that either pays (for some) or uses the national registries. I am more curious about the meat and potatoes of this company and their track records in regards to Pharmacyte.
For everyone's reading enjoyment about the psychology of pricing!
http://www.livescience.com/33045-why-do-most-prices-end-in-99-cents-.html
https://en.wikipedia.org/wiki/Psychological_pricing
Thank you for clarifying. They only have information with the companies they have contracted with and access to the national databases as do all health care agencies. They do contractual work and further "manage" trials/qualitative/quantitative information. There are a lot of companies that do similar work however it is much needed work regardless.
There information can be found here:
http://www.td2inc.com/preclinical-development
I have a decent background on how this works and how big data plays a role. The database he is speaking of is found here:
http://www.td2inc.com/clinical-research/clinical-trial-management
They use the national database I have referenced, as well as the subsequent sites they have under contract, are who TD2 uses to recruit patients.
I just reread your post so I want to share one of the largest databases that has probably the widest net here within the U.S.:
The nationally recognized National Cancer Database (NCDB)—jointly sponsored by the American College of Surgeons and the American Cancer Society—is a clinical oncology database sourced from hospital registry data that are collected in more than 1,500 Commission on Cancer (CoC)-accredited facilities. NCDB data are used to analyze and track patients with malignant neoplastic diseases, their treatments, and outcomes. Data represent more than 70 percent of newly diagnosed cancer cases nationwide and more than 34 million historical records.
Online reporting tools are available to provide your program with comparative benchmarks for similar programs aggregated throughout your state, region, and across CoC-accredited programs as a whole. Additional reporting tools provide quality related performance measures in comparison to aggregated CoC-accredited programs, including quality improvement, quality assurance, and surveillance measures. Through comparison and evaluation, you can proactively improve delivery and quality of care for cancer patients in your cancer program.
I may be misunderstanding you based off your response however all databases or anything to do with private health information has to be deidentified. There are only a few exceptions but how population health and disease surveillance works they are have to take steps to ensure the privacy of the patient unless the patient explicitly signs for it otherwise. The only circumstances is when they are able to do this is in those cases and further they would have to be at a site that is geared for that. EMR's are the new way they are doing such analysis and they deidentify on the reports. They would have to request the provider to contact the patients requesting their participation.
All databases have to follow the same protocol. It's a liability if they do not. I am not sure what specific database you are talking about but they are regulated by federal law.
Just to clarify about databases within the US (Europe is similar):
All the information is deintified. It's against US law to have identifiable information about a patient- this means anything that can lead to their identification. Europe has similar laws.
Cancer Surveillance Programs
in the United States
Cancer surveillance is the ongoing, timely, and systematic collection and analysis of information on new cancer cases, extent of disease, screening tests, treatment, survival, and cancer deaths. What that really means is that scientists and health officials are keeping an eye on cancer and tracking it for public health reasons.
This cancer information (data) can be used to look for trends over time, to find cancer patterns in certain regions or groups of people, and/or to show whether screening and other prevention measures are making a difference. For instance, the data can show differences in cancer rates and death in certain states or regions of the country.
Regions without such registries don’t know how many cancer cases there are in that location, or how many people die from cancer. Registries and surveillance information are key parts of cancer prevention and control efforts.
No single surveillance program in the United States collects data on all cancers diagnosed each year. Certain segments of the US population are covered by separate programs sponsored by government or private organizations, and these programs provide reliable data on their segments. These programs are built on a foundation of existing cancer registries or registries that are set up throughout the country to record and report cancer cases in the areas they cover.
Cancer registries
Data on cancer in the United States is collected through several systems of registries. The data collected depends on the purpose of the registry. Two types are:
Hospital registries, which may be part of a facility’s cancer program
Population-based registries, which are usually tied to state health departments
Hospital registries provide complex data used to evaluate patient care within the hospital. This data may be focused on things like care of the cancer patient and educating health care providers. Some hospitals pool their data and use the collected information to learn more about the course of cancer. The pooled data can be used in studies that compare patterns of care among providers, population subsets, or geographic regions.
Population-based registries, such as those under state health departments, collect information on all cases diagnosed within a certain geographic area. Population-based registries in cities and states collect and pull together information from multiple reporting facilities within their geographic regions that can include:
Hospitals
Doctors’ offices
Nursing homes
Pathology laboratories
Ambulatory care facilities or clinics
Radiation and chemotherapy treatment centers
Other cancer care facilities
These registries provide data that can show things like new cancer cases (incidence) and death rates (mortality) across regions of the country. They can look at cancer rates in certain types of jobs, or see if cancer survival is improving. They can also watch cancer trends over time to find out if the rate of a type of cancer is going up or down. They can be used to keep an eye on which age and racial groups are most affected by different types of cancer.
Information from cancer registries helps guide cancer prevention and control programs that are focused on changing certain behaviors (like smoking) and reducing other environmental risks. Cancer registries can help identify a need for increased cancer screening in a certain region or area.
Collecting the information
Registries are usually staffed with cancer registrars who have met stringent standards of training, testing, and continuing education. The highest level is Certified Tumor Registrar (CTR). These registrars compile timely, accurate, and complete cancer information to report to the registry.
Cancer registration begins with casefinding, or identifying people with cancer who have sought care at hospitals and other medical care settings. Most often, it’s the patient’s doctor who starts the data record, noting the cancer site and type, patient demographics (like gender, race, and age), and extent of disease (or stage) in the medical record. Some cancer registry programs require that the registrar summarize and record certain other information from the patient record, such as type of treatment, and follow up each year to track cancer recurrence and survival.
Confidentiality of personal information
Before any statistics or other cancer information is published, the law requires that identifying details be removed so that nothing can be traced back to any one person. This is sometimes called de-identified data.
Major cancer surveillance programs
The following are brief descriptions of the major cancer surveillance programs in the United States.
National Cancer Data Base
Established in 1989, the National Cancer Data Base (NCDB) is a joint program of hospital registries of the Commission on Cancer (COC) and the American Cancer Society. Its purpose is to ensure quality cancer care by providing data to:
Evaluate patient management within hospitals and other treatment centers
Make comparisons of cancer care and outcomes between institutions
Set standards to help improve quality of cancer care
Groups of specialists design and monitor patient care evaluation (PCE) studies to provide timely information on patterns of care related to geographic, socioeconomic, and clinical factors. To share the results of PCE studies, the findings are presented at professional meetings and reports are published in peer-reviewed journals. More than 1,500 cancer treatment centers in the United States and Puerto Rico contribute data to the NCDB. The NCDB contains about 29 million records from hospital cancer registries.
The Surveillance, Epidemiology and End Results Program
The National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) program is a large population-based registry. It collects information from certain geographic areas which represent 28% of the US population, including:
Cancer incidence (new cases)
Survival
Prevalence (number of people living with cancer during a given time period)
The NCI contracts with non-profit organizations to collect data on new cancer diagnoses in the designated geographic locations. Cases are followed up each year to determine survival. The data, along with data on cancer-related deaths from the entire US from the National Center for Health Statistics (NCHS), are analyzed and are published annually in the SEER Cancer Statistics Review.
National Program of Cancer Registries
The National Program of Cancer Registries (NPCR) of the Center for Disease Control and Prevention (CDC) supports population-based registries in state health departments. This program was established by the Cancer Registries Amendments Act in 1992 to respond to the need to collect data on larger percentages of state populations. This legislation authorizes the CDC to provide funds to states and territories to:
Improve existing cancer registries
Plan and set up registries where they don’t exist
Develop model legislation and regulations for states to enhance success of registry operations
Set standards for completeness, timeliness, and quality
Provide training for registry staff
Help set up a computerized reporting and data processing system
State cancer registries are computerized and have many public health uses. They are designed to:
Monitor cancer trends over time.
Look for cancer patterns in different groups of people.
Guide planning and evaluation of cancer control programs. For instance, look at whether prevention, screening, and treatment efforts are making a difference.
Help set priorities for allocating health resources.
Advance clinical, epidemiologic, and health services research.
Provide information for a national data base of cancer incidence.
Before the NPCR was established, 10 states had no registry, and most states with registries lacked the resources and legislative support they needed to gather complete data. Today, the NPCR supports central cancer registries in 45 states, the District of Columbia, Puerto Rico, and the US Pacific Island Jurisdictions. The data represent 96% of the US population.
Together, the NPCR and the National Cancer Institute’s SEER Program collect data for the entire US population.
The future for registries
Future directions for cancer registries include support of more electronic information sharing. It’s hoped this will allow better studies on things like access to care for people with cancer and survivorship. The CDC is already planning ways to let research be done on de-identified cancer information, which should result in doctors getting more complete information on cancer and its care.
References
American College of Surgeons Cancer Programs. National Cancer Data Base (NCDB). Accessed at www.facs.org/cancer/ncdb/index.html on March 19, 2014.
Centers for Disease Control and Prevention. National Program of Cancer Registries (NPCR). Accessed at www.cdc.gov/cancer/npcr/about.htm on March 20, 2014.
National Cancer Institute. Surveillance, Epidemiology and End Results. Accessed at http://seer.cancer.gov/index.html on March 20, 2014.
National Cancer Institute. Surveillance, Epidemiology and End Results. SEER training modules: Cancer Registration. Accessed at http://training.seer.cancer.gov/registration/ on March 20, 2014.
Here is an article based on category of disease and probability of approval. It also highlights the probability based on phase results.
http://www.reuters.com/article/us-pharmaceuticals-success-idUSTRE71D2U920110214
Generally speaking: Any chronic disease is a great opportunity for targeted interventions or curative treatments. Biomedical sciences are advancing and it's unfortunate the previous 2 administrations have not put an emphasis on STEM in academia.
I thought they were referring to the the other trials per their message.
Here is a link with where all their R&D are in the pipeline for those who may be confused.
http://pharmacyte.com/research-development/
They need to do a phase 1. They need a larger pool in order to ensure dosage ect. Also, it needs to be larger to see if the efficacy is statistically significant. To my understanding the designation that the drug has received helps move the process along quicker but they still need to follow the scientific methods that have been designated.